| Cardiovascular Risk Management |
1 |
1 |
| Clinical Guidelines |
0 |
0.86 |
| Lipids Management |
0 |
0.85 |
| Cardiovascular Imaging |
0 |
0.74 |
| Angina Pectoris |
0 |
0.47 |
| Acute Coronary Syndrome |
0 |
0.4 |
| Cardiomyopathy |
0 |
0.4 |
| Arrhythmia |
0 |
0.36 |
| Beta-Adrenergic Agonist |
0 |
0.26 |
| Type 2 Diabetes Mellitus |
0 |
0.25 |
| Ejection Fraction |
0 |
0.24 |
| Exercise |
0 |
0.2 |
| Coronary Artery Disease (CAD) |
0 |
0.19 |
| PCSK9 |
0 |
0.18 |
| Heart |
0 |
0.13 |
| Myocardial Infarction (MI) |
0 |
0.13 |
| Osteoarthritis |
0 |
0.13 |
| Physical Medicine and Rehabilitation (PMR) |
0 |
0.13 |
| Quality of Life |
0 |
0.13 |
| Tobacco Cessation |
0 |
0.13 |
| GLP-1 Receptor Agonist |
0 |
0.11 |
| Calcium Channel Blockers |
0 |
0.09 |
| Angiography |
0 |
0.07 |
| Antianginals |
0 |
0.07 |
| Artery |
0 |
0.07 |
| Calcium |
0 |
0.07 |
| Cardiac Rehabilitation |
0 |
0.07 |
| Dietary Supplements |
0 |
0.07 |
| E-cigarettes |
0 |
0.07 |
| Fatty Acids |
0 |
0.07 |
| Fish Oil |
0 |
0.07 |
| Infarction |
0 |
0.07 |
| Ischemic Cardiomyopathy |
0 |
0.07 |
| Other Specialty |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| SGLT2 Inhibitor |
0 |
0.07 |
| Shared Decision-Making |
0 |
0.07 |
| Stable Angina |
0 |
0.07 |
| Statins |
0 |
0.07 |
| Stenosis |
0 |
0.07 |
| Vitamin |
0 |
0.07 |